Left ventricular hypertrophy is a leading risk factor for cardiovascular morbidity and mortality.
Although reverse ventricular remodelling was long thought to be irreversible, evidence from …

Myocardial infarction (MI) is the leading cause of death and morbidity worldwide, with an
incidence relatively high in developed countries and rapidly growing in developing …

Approximately 7 million people are affected by acute myocardial infarction (MI) each year,
and despite significant therapeutic and diagnostic advancements, MI remains a leading …

Introduction: We sought to investigate the prognostic impact of incident left ventricular (LV)
systolic dysfunction at the chronic phase of acute myocardial infarction (AMI). Materials and …

Clinical practice guidelines published by the European Society of Cardiology and the
American College of Cardiology/American Heart Association summarize the available …

Background Dilated cardiomyopathy (DCMP) is characterized by ventricular chamber
enlargement and systolic dysfunction which may cause heart failure. Patients with DCMP …

Background: Despite the recommendations from mainstream guidelines, the use of
angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) …

There have been few studies of angiotensin receptor blocker (ARB) dose in myocardial
infarction (MI) with preserved left ventricular (LV) systolic function. We evaluated the …

Background: For the Asian patients with STEMI undergoing PCI, ACEIs are known to have a
better outcome than ARBs. However, there is limited evidence to suggest so. Methods …

Актуальность темы. Разработка новых эффективных и безопасных лекарственных
средств растительного происхождения, влияющих на сердечнососудистую и …